While both organizations have considerable experience in overseeing large clinical development programmes, the merger combines IRC’s focus on federally-funded studies and device trials with ERC’s expertise in multi-centre assessments.
Under the terms of the proposed merger, the two organizations will begin implementing an integration plan immediately while they continue to operate as their respective organizations.
Further details of the plan and its proposed time lines have not been disclosed.